First-ever RNA editing trial in US gets clearance, pitting ‘exon editing’ technology against vision loss
29 Jan 2024
Clinical StudyIND
The FDA told the Boston startup Ascidian Therapeutics that it can begin the first clinical tests of a therapy that “rewrites” RNA to correct roughly two-thirds of the genetic typos responsible for an inherited form of vision loss called Stargardt disease.
Tinkering with RNA, the short-lived cousin of DNA, could lower some of the hypothetical risks associated with technologies like CRISPR that make permanent changes to the genome. That argument, made by Ascidian and other biotechs developing RNA editing therapies, now has backing from US regulators.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.